Isla S Mackenzie

List of Publications by Citations

Source: https://exaly.com/author-pdf/4158173/isla-s-mackenzie-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

3,421
citations

4,061
ext. papers

4,061
ext. citations

27
h-index
g-index

4.78
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 69 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet, The</i> , 2015 , 386, 2059-2068 | 40 | 632 |
| 68 | Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 147-52 | 9.4 | 311 |
| 67 | C-reactive protein is associated with arterial stiffness in apparently healthy individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 969-74 | 9.4 | 309 |
| 66 | Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. <i>Hypertension</i> , 2006 , 48, 602-8 | 8.5 | 290 |
| 65 | Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. <i>Hypertension</i> , 2009 , 54, 409-13 | 8.5 | 176 |
| 64 | Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 100-9 | 5.6 | 150 |
| 63 | Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. <i>Circulation</i> , 2004 , 109, 1718-23 | 16.7 | 146 |
| 62 | Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 464-475 | 18.1 | 126 |
| 61 | Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1891-5 | 9.4 | 74 |
| 60 | Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2016 , 4, 136-47 | 18.1 | 72 |
| 59 | Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2020 , 396, 1745-1757 | 40 | 70 |
| 58 | Pioglitazone and bladder cancer: a propensity score matched cohort study. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 254-9 | 3.8 | 69 |
| 57 | Impact of allopurinol use on urate concentration and cardiovascular outcome. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 600-7 | 3.8 | 67 |
| 56 | Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. <i>BMJ Open</i> , 2014 , 4, e005354 | 3 | 64 |
| 55 | Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 57 |
| 54 | Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. <i>BMJ, The</i> , 2013 , 347, f6954 | 5.9 | 51 |
| 53 | Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. <i>BMJ Open</i> , 2016 , 6, e013774 | 3 | 48 |

| 52 | Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. <i>BMJ, The</i> , 2012 , 345, e4447 | 5.9 | 46 | |
|----|--|---------------|----|--|
| 51 | Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. <i>Hypertension</i> , 2014 , 63, 706-12 | 8.5 | 45 | |
| 50 | Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). <i>European Heart Journal</i> , 2017 , 38, 1843-1850 | 9.5 | 42 | |
| 49 | Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. <i>BMJ Open</i> , 2016 , 6, e010313 | 3 | 39 | |
| 48 | The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. <i>European Journal of Endocrinology</i> , 2007 , 157, 533-7 | 6.5 | 38 | |
| 47 | Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 801 | - ₹ †8 | 35 | |
| 46 | Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 653-663 | 3.8 | 32 | |
| 45 | Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 2014 , 44, 25-30 | 5.3 | 30 | |
| 44 | Exaggerated Exercise Blood Pressure Response and Future Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 837-44 | 2.3 | 30 | |
| 43 | Promoting public awareness of randomised clinical trials using the media: the TGet RandomisedT campaign. <i>British Journal of Clinical Pharmacology</i> , 2010 , 69, 128-35 | 3.8 | 30 | |
| 42 | Antiplatelet drug interactions. Journal of Internal Medicine, 2010, 268, 516-29 | 10.8 | 26 | |
| 41 | Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. British Journal of Clinical Pharmacology, 2017 , 83, 1298-1308 | 3.8 | 25 | |
| 40 | Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. <i>Respiratory Research</i> , 2014 , 15, 141 | 7.3 | 25 | |
| 39 | Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?. <i>Trials</i> , 2015 , 16, 80 | 2.8 | 24 | |
| 38 | Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. <i>Arthritis Research and Therapy</i> , 2008 , 10 Suppl 2, S3 | 5.7 | 21 | |
| 37 | Renal artery stenosis-when to screen, what to stent?. Current Atherosclerosis Reports, 2014, 16, 416 | 6 | 19 | |
| 36 | Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1880-1895 | 3.8 | 18 | |
| 35 | Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT). <i>BMJ</i> | 3 | 17 | |

| 34 | Treatment of osteoarthritis in hypertensive patients. Expert Opinion on Pharmacotherapy, 2010, 11, 393 | 3- <u>4</u> 03 | 17 |
|----|--|----------------|----|
| 33 | Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 133-41 | 2.8 | 12 |
| 32 | Molecular and clinical investigations in patients with low-renin hypertension. <i>Clinical and Experimental Nephrology</i> , 2009 , 13, 1-8 | 2.5 | 12 |
| 31 | Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020 , 41, 1606-1607 | 9.5 | 11 |
| 30 | Effectiveness of newspaper advertising for patient recruitment into a clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 1064-72 | 3.8 | 10 |
| 29 | Pseudopheochromocytoma. <i>Journal of Hypertension</i> , 2007 , 25, 2204-6 | 1.9 | 9 |
| 28 | Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial. <i>BMJ Open</i> , 2015 , 5, e007645 | 3 | 8 |
| 27 | The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment. <i>Trials</i> , 2017 , 18, 557 | 2.8 | 8 |
| 26 | Managing security and privacy concerns over data storage in healthcare research. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 885-93 | 2.6 | 8 |
| 25 | The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 518-23 | 3.8 | 8 |
| 24 | Cardiovascular risk associated with sodium-containing medicines. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1515-23 | 4.1 | 7 |
| 23 | Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment. <i>Clinical Medicine</i> , 2002 , 2, 465-73 | 1.9 | 7 |
| 22 | Cluster randomized trials of prescription medicines or prescribing policy: public and general practitioner opinions in Scotland. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 354-61 | 3.8 | 4 |
| 21 | AT2 receptor stimulation may halt progression of pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1073, 436-43 | 6.5 | 4 |
| 20 | Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 296-305 | 2.6 | 4 |
| 19 | A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial. <i>Clinical Trials</i> , 2016 , 13, 665-670 | 2.2 | 4 |
| 18 | Bilateral adrenal masses: phaeochromocytoma or melanoma?. <i>Journal of the Royal Society of Medicine</i> , 2006 , 99, 153-5 | 2.3 | 3 |
| 17 | Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1129-1140 | 3.8 | 3 |

LIST OF PUBLICATIONS

| 16 | Ibuprofen and Paracetamol: Acceptably Safe for All?. Drug Safety, 2018, 41, 999-1001 | 5.1 | 2 |
|----|---|-----|---|
| 15 | Grand Rounds at the British Hypertension Society: renal artery stenosis. <i>Journal of Human Hypertension</i> , 2007 , 21, 750-5 | 2.6 | 2 |
| 14 | Evaluating Diuretics in Normal Care (EVIDENCE): protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension. <i>Trials</i> , 2021 , 22, 814 | 2.8 | 2 |
| 13 | Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. <i>British Journal of Clinical Pharmacology</i> , 2021 , | 3.8 | 2 |
| 12 | Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations. <i>BMC Medical Research Methodology</i> , 2019 , 19, 24 | 4.7 | 1 |
| 11 | Cluster randomised trials of prescribing policy: an ethical approach to generating drug safety evidence? A discussion of the ethical application of a new research method. <i>Trials</i> , 2020 , 21, 477 | 2.8 | 1 |
| 10 | Poster advertisements in practice waiting rooms to recruit patients to the Treatment In Morning vs. Evening (TIME) online study. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 325-6 | 3.8 | 1 |
| 9 | Initial cardiovascular treatment patterns during the first 90 days following an incident cardiovascular event. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1043-1055 | 3.8 | 1 |
| 8 | Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 482-491 | 2.6 | 1 |
| 7 | Changes in prescribing rates of sodium-containing medications in the UK from 2009 to 2018: a cross-sectional study with interrupted time series analysis. <i>BMJ Open</i> , 2021 , 11, e043566 | 3 | 1 |
| 6 | Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study. <i>Journal of Human Hypertension</i> , 2021 , | 2.6 | 1 |
| 5 | Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study. <i>BMJ Open</i> , 2022 , 12, e060583 | 3 | O |
| 4 | Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures. <i>BMJ Open</i> , 2018 , 8, e021890 | 3 | |
| 3 | Cardiovascular safety of febuxostat - AuthorsTreply. <i>Lancet, The</i> , 2021 , 398, 955-956 | 40 | |
| 2 | European Association for Clinical Pharmacology and Therapeutics-9th congress. 12-15 July 2009, Edinburgh, UK. <i>IDrugs: the Investigational Drugs Journal</i> , 2009 , 12, 550-4 | | |
| 1 | Evaluating Diuretics in Normal Care (EVIDENCE): a feasibility report of a pilot cluster randomised trial of prescribing policy in primary care to compare the effectiveness of thiazide-type diuretics in hypertension <i>Pilot and Feasibility Studies</i> , 2022 , 8, 62 | 1.9 | |